BIRC5 and cancer: Several clinical studies are ongoing with the therapeutic aim of inhibiting AURKB [46] in an effort to target genes involved in the “BIRC5 cancer network” and clinical responses indicate a central role of this pathway in proliferating leukaemic cells.